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Context: Patients with intermediate-risk non–muscle-invasive bladder cancer (NMIBC)
may pose a clinical dilemma without an agreed evidence-based decision tree for
personalized treatment.
Objective: To perform a systematic review and network meta-analysis (NMA) to sum-
marize available evidence on the oncologic outcomes of intravesical therapy in patients
with intermediate-risk NMIBC.
Evidence acquisition: The MEDLINE, EMBASE, and ClinicalTrials.gov databases were
searched in October 2020 according to the Preferred Reporting Items for Systematic
Reviews and Meta-analyses statement. Studies were deemed eligible if they reported on
oncologic outcomes in patients with intermediate-risk NMIBC treated with trans-
urethral resection of bladder tumor with and without intravesical chemotherapy or
bacillus Calmette-Guérin (BCG) immunotherapy.
Evidence synthesis: Twelve studies were included in a qualitative synthesis (systematicNetwork meta-analysis review); three were dee
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recurrence risk. Chemotherapy with maintenance was associated with a lower
likelihood of 5-yr recurrence than chemotherapy without maintenance (odds ratio
[OR] 0.51, 95% credible interval [CI] 0.26–1.03). Immunotherapy, regardless of
whether a full- or reduced-dose regimen, was not associated with a significantly
lower likelihood of 5-yr recurrence when compared with chemotherapy without
maintenance (OR 0.90, 95% CI 0.39–2.11 vs OR 0.93, 95% CI 0.40–2.19). Analysis of the
treatment ranking revealed that chemotherapy with maintenance had the lowest 5-
yr recurrence risk (P score 0.9666).
Conclusions: Our analysis indicates that chemotherapy with a maintenance regimen
confers a superior oncologic benefit in terms of 5-yr recurrence risk compared to
chemotherapy without maintenance in patients with intermediate-risk NMIBC.
Regardless of the dose regimen, immunotherapy with BCG does not appear to be
superior to chemotherapy in patients with intermediate-risk NMIBC in term of
disease recurrence. However, owing to the lack of comparative studies, there is an
unmet need for well-designed, large-scale trials to validate our findings and generate
robust evidence on disease recurrence and progression.
Patient summary: A maintenance schedule of chemotherapy reduces the rate of
long-term recurrence of bladder cancer that has not invaded the bladder muscle.
Chemotherapy inserted directly into the bladder and immunotherapy without
maintenance schedules seem to have limited benefit in preventing cancer recurrence.
© 2021 Published by Elsevier B.V. on behalf of European Association of Urology.
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Bladder cancer is the sixth most commonly diagnosed
cancer worldwide [1,2]. Approximately 75% of bladder can-
cer patients present with non–muscle-invasive bladder
cancer (NMIBC) [3]. NMIBC is a heterogeneous disease
associated with a wide array of oncologic outcomes, which
warrants an accurate and practical risk stratification strat-
egy for treatment planning and patient counseling [4]. Sev-
eral models, such as those of the European Organization for
Research and Treatment of Cancer (EORTC) [5] and Club
Urologico Espano de Tratamiento Oncologico [6], have been
proposed for stratifying patients with NMIBC in terms of
recurrence and progression risk. However, despite their
ease of use, the predictive accuracy of these models is
limited by intragroup heterogeneity among patients
[7]. Moreover, the models do not take into account adverse
pathologic features, such as lymphovascular invasion and
variant histologies, that are associated with more aggressive
disease and poor response to intravesical therapy [8–
12]. Consequently, optimal decision-making remains chal-
lenging, especially for patients with intermediate-risk dis-
ease, the largest risk group among NMIBC patients.
Currently, adjuvant intravesical immunotherapy with
bacillus Calmette-Guérin (BCG) or intravesical chemother-
apy is the standard of care for patients with intermediate-
and high-risk NMIBC [13]. Since treatment options and
follow-up are dependent on risk stratification, patients with
intermediate-risk NMIBC are vulnerable to inadequate ther-
apy owing to the poorly defined and overlapping diagnostic
criteria [13]. However, unnecessary adverse events and
costs associated with treatment may outweigh the possible
benefits for patients with intermediate-risk NMIBC. Conse-
quently, patients with intermediate-risk NMIBC may pose a
clinical dilemma without an agreed evidence-based deci-
sion tree for personalized treatment.
The primary aim of this systematic review and network
meta-analysis (NMA) was to determine the oncologicPlease cite this article in press as: Laukhtina E, et al. Intravesical Th
Bladder Cancer: A Systematic Review and Network Meta-analysis
10.1016/j.euf.2021.03.016outcomes of intravesical therapy among patients with inter-
mediate-risk NMIBC. Such findings would help in decision-
making, patient counseling, and trial design.
2. Evidence acquisition
2.1. Protocol
This systematic review and NMA were conducted according
to the Preferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) extension statement for network
meta-analysis [14]. The study protocol was registered a
priori on the International Prospective Register of System-
atic Reviews (PROSPERO; registration ID CRD42020212851).
2.2. Data sources and searches
The MEDLINE, EMBASE, and ClinicalTrials.gov databases were
searched in October 2020 to identify studies reporting on the
oncologic outcomes of intravesical therapy for patients with
intermediate-risk NMIBC. A comprehensive systematic liter-
ature search was independently performed by two authors.
Terms and keywords such as urinary bladder neoplasms,
non–muscle-invasive bladder cancer, intermediate risk non-
–muscle-invasive bladder cancer, NMIBC, oncologic out-
comes, local recurrence, disease-free survival, and overall
survival were used to perform the search. The primary out-
comes of interest were oncologic outcomes, including pro-
gression-free survival (PFS), recurrence-free survival (RFS),
disease-free survival (DFS), and overall survival (OS).
After removing duplicates, two independent reviewers
screened the titles and abstracts. Any citation that either
reviewer thought should be included or for which suitabil-
ity for inclusion was unclear was identified for full-text
screening. Subsequently, full texts of eligible articles were
reviewed for final inclusion and data extraction. Any dis-
crepancy during the primary and secondary literature
screenings were resolved by referring to the senior author.erapy in Patients with Intermediate-risk Non–muscle-invasive
 of Disease Recurrence. Eur Urol Focus (2021), https://doi.org/
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We included randomized controlled trials (RCTs) that
reported on oncologic outcomes of intravesical therapy
for patients with intermediate-risk NMIBC. PICOS (popula-
tion, intervention, control, outcomes, and study design) for
this study was as follows: patients with intermediate-risk
NMIBC according to the European Association of Urology
(EAU) or the American Urological Association (AUA) guide-
lines, treated with transurethral resection of bladder tumor
(TURBT) and intravesical chemotherapy or immunotherapy
(BCG) compared to a control group including patients trea-
ted with TURBT alone or cohorts receiving single adjuvant
therapy. The outcomes were oncologic outcomes, including
PFS, RFS, DFS, and/or OS.
We excluded reviews, letters, editorials, animal studies,
study protocols, case reports, meeting abstracts, replies
from authors, brief correspondence, and articles not pub-
lished in English. Furthermore, we excluded studies that did
not provide data regarding the oncologic outcomes. Refer-
ences of all the papers included were scanned for additional
studies of interest.
2.4. Data extraction
Data from each study were independently extracted by two
reviewers. Extracted data included the following: study iden-
tifiers, study design, number of participants, number of par-
ticipants within different NMIBC risk strata, oncologic out-
comes, and demographic and clinical characteristics of the
patients. Subsequently, the hazard ratio (HR) and 95% confi-
dence interval for the oncologic outcomes were retrieved.
2.5. Risk-of-bias assessment
The risk of bias (RoB) was evaluated according to the Risk of
Bias in Non-randomized Studies of Interventions (ROBINS-I)
tool. This tool is based on seven domains that include bias
due to confounding, participant selection, classification of
interventions, deviations from the intended intervention,
missing data, measurement of outcomes, and selection of
the reported result (Supplementary Table 1). The RoB for
each study was assessed independently by two authors.
Disagreements were resolved via consultation with the co-
authors.
2.6. Statistical analyses
NMA was used for simultaneous comparison of the 5-yr
recurrence risk for multiple treatment strategies and pool-
ing of direct and indirect evidence. For assessment of the 5-
yr recurrence risk, arm-based analyses were performed to
estimate the odds ratio (OR) of the 5-yr recurrence risk and
95% credible interval (CI) from the raw data presented in the
manuscripts included [15]. The relative ranking of the dif-
ferent treatments for each outcome was estimated using the
P score, which can be considered a frequentist analog to the
surface under the cumulative ranking curves [16,17]. Net-
work plots were used to illustrate the connectivity of thePlease cite this article in press as: Laukhtina E, et al. Intravesical Th
Bladder Cancer: A Systematic Review and Network Meta-analysis
10.1016/j.euf.2021.03.016treatment networks in terms of 5-yr recurrence risk. R v1.14,
framework 2.21 (R Foundation for Statistical Computing,
Vienna, Austria) was used for the NMA.
3. Evidence synthesis
3.1. Description of the studies included
The literature search identified 522 unique references. Of
these, 192 were excluded because of duplication and
255 because of unrelated outcomes during the screening
process (Fig. 1). Of the 75 full-text articles assessed for
eligibility, 63 were excluded based on the selection criteria.
Twelve studies were finally included in the qualitative
synthesis (systematic review) [18–29]; three were deemed
eligible for quantitative synthesis (NMA) [18,26,27]. Table 1
summarizes the characteristics of the studies.
We found significant heterogeneity across the studies in
terms of treatment used for patients with intermediate-risk
NMIBC. Ten studies reported data on different intravesical
therapy regimens [18,19,22–29]. Among chemotherapeu-
tics, epirubicin was used in four studies, mitomycin C
(MMC) in three, and pirarubicin in one. Immunotherapy
with BCG was used in four studies. Two studies reported
outcomes for laser vaporization of bladder tumor (LVRBT)
compared to TURBT [20,21].
3.2. Principal findings
3.2.1. Oncologic outcomes
In terms of oncologic outcomes, all 12 studies reported on
the recurrence rate [18–29], eight reported data on the
progression rate [18,19,23,24,26–29], and only two
reported on survival outcomes such as OS and cancer-
specific survival (CSS) [26,28]. Table 2 summarizes oncol-
ogic outcomes such as recurrence and progression rates
among the studies.
3.2.1.1. Recurrence risk. All studies included reported the risk
of recurrence for different treatment strategies for patients
with intermediate-risk NMIBC (Table 2). Regarding intra-
vesical chemotherapy, Naya et al [24] reported that among
patients with intermediate-risk NMIBC, the 3-yr RFS rate
was worse for those who received a single immediate
installation of pirarubicin compared to those who received
additional instillations of pirarubicin. Kelly et al [23] found
that celecoxib added to a standard-of-care single intrave-
sical MMC instillation within 24 h following TURBT did not
improve 3-yr RFS.
Regarding intravesical immunotherapy with BCG, Gupta
et al [22] reported no difference in recurrence rate between
patients treated with monthly BCG for 12 doses and patients
receiving BCG maintenance according to the SWOG proto-
col. Likewise, Oddens et al [25] reported that patients with
intermediate-risk NMIBC treated with a full-dose schedule
do not benefit from 1 yr of maintenance BCG therapy.
Comparing the efficacy of maintenance with chemotherapy
and BCG, Sylvester et al [28] reported statistically significant
worse outcomes in terms of 9.2-yr recurrence and distanterapy in Patients with Intermediate-risk Non–muscle-invasive
 of Disease Recurrence. Eur Urol Focus (2021), https://doi.org/
Fig. 1 – Flow diagram of the study selection procedure for the systematic review and network meta-analysis.
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to those receiving BCG (both with 3-yr maintenance).
Two studies compared the effectiveness of LVRBT and
TURBT followed by intravesical therapy. Xu et al [20]
reported no significant difference in 2-yr recurrence rates
between KTP laser and standard TURBT, both following
pirarubicin instillations. Zhang et al [21] did not find differ-
ences in 1- and 3-yr recurrence rates between LVRBT with
thulium laser and TURBT; in both groups, surgery was
followed by epirubicin instillations.
In summary, according to the current literature, chemo-
therapy with maintenance seems to reduce the recurrence
rate among patients with intermediate-risk NMIBC, while 1
yr of maintenance BCG therapy does not appear to affect
recurrence outcomes in these patients. Different endo-
scopic procedures also do not demonstrate differences in
recurrence risk among patients with intermediate-risk
NMIBC.
3.2.1.2. Progression risk. Eight of the studies included reported
data on the progression rate (Table 2). Sylvester et al [28] did
not find a statistically significant difference in 9.2-yr pro-
gression rate between patients receiving epirubicin andPlease cite this article in press as: Laukhtina E, et al. Intravesical Th
Bladder Cancer: A Systematic Review and Network Meta-analysis
10.1016/j.euf.2021.03.016those receiving BCG (both with 3-yr maintenance). Simi-
larly, Ojea et al [26] did not find a difference in progression
rates among patients with intermediate-risk NMIBC treated
with MMC or full or low doses of BCG (27 mg and 14.5 mg).
Kelly et al [23] found that celecoxib did not decrease the
progression rate more than a single immediate intravesical
MMC instillation alone in intermediate-risk NMIBC. The
current data indicate that intravesical therapies do not
differ in terms of the progression rate. However, these data
need to be supported by well-designed and controlled
large-scale trials.
3.2.1.3. Survival outcomes. Among survival outcomes, OS and
CSS were reported in two studies of patients with intermedi-
ate-risk NMIBC treated with epirubicin, BCG, or MMC. Data
from the EORTC trials [28] showed all-cause mortality of
38.8% among patients treated with epirubicin with 3-yr
maintenance, compared to 30.3% among those treated with
BCG 3-yr maintenance (HR 0.79, 95% CI 0.58–1.09; p = 0.14);
cancer-specific mortality was 7.1% and 2.4%, respectively (HR
0.35, 95% CI 0.14–0.86; p = 0.02). Ojea et al [26] found cancer-
specific mortalityof4.7%,3%,and3.6% amongpatients treated
with MMC, BCG 27 mg, and BCG 14.5 mg, respectively, in aerapy in Patients with Intermediate-risk Non–muscle-invasive
 of Disease Recurrence. Eur Urol Focus (2021), https://doi.org/
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Kelly 2018 [23] UK RCT 126/472 69/57 Twice daily
celecoxib post
TURBT + MMC (IR)
or BCG (HiR)
Placebo post
TURBT + MMC (IR)
or BCG (HiR)
EAU guidelines Median 44 mo
(IQR 36–57)






weekly for 8 wk
EAU guidelines Median 36 mo
Oddens 2012 [25] Netherlands RCT 789/1355 1/3 dose, 1 yr: 192
FD, 1 yr: 191v
1/3 dose, 3 yr: 218
FD, 3 yr: 188
1/3 dose BCG + 1-yr
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FD BCG + 1-yr
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1/3 dose BCG + 3-yr
maintenance post
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Sylvester 2009 [28] Europe
(Belgium)
RCT 497/837 BCG: 161
BCG + INH: 166
Epi: 170








Turkeri 2010 [29] Turkey RCT 143/143 68/75 Single instillation
of Epi post TURBT
Double instillations









Xu 2015 [20] China RCT 116/193 56/60 KTP laser + THP TURBT + THP EAU guidelines NR
Zhang 2015 [21] China RCT 87/292 43/44 LVRBT + Epi TURBT + Epi EAU guidelines Duration 36 mo
BCG = bacillus Calmette-Guérin; CIS = carcinoma in situ; EAU = European Association of Urology; Epi = epirubicin; FD = full dose; G = grade; HiR = high risk; INH
= isoniazid; IQR = interquartile range; IR = intermediate risk; KTP = potassium-titanyl-phosphate; LVRBT = laser vaporesection of bladder tumor; MMC =
mitomycin C; RCT = randomized controlled trial; SWOG = Southwestern Oncology Group; THP = pirarubicin; TUR/TURBT = transurethral resection of bladder
tumor; Tx = treatment.
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there are only limited data on survival outcomes for patients
with intermediate-risk NMIBC. Nevertheless, BCG appears to
have a marginal benefit compared to chemotherapy in terms
of long-term OS and CSS.Please cite this article in press as: Laukhtina E, et al. Intravesical Th
Bladder Cancer: A Systematic Review and Network Meta-analysis
10.1016/j.euf.2021.03.0163.3. Network meta-analysis
For quantitative synthesis in the NMA, therapy regimens
from three studies were categorized into groups as fol-
lows: (1) chemotherapy as standard regimen ([total oferapy in Patients with Intermediate-risk Non–muscle-invasive
 of Disease Recurrence. Eur Urol Focus (2021), https://doi.org/
Fig. 2 – Network plot showing the association of treatment with the 5-
yr recurrence risk in intermediate-risk non–muscle-invasive bladder
cancer. The plot shows interconnections between different therapy
regimens (represented by a node). Connections between different
therapy regimens are represented through links, and the numbers
indicate the number of studies.
Table 2 – Progression and recurrence rates for patients with intermediate-risk non–muscle invasive bladder cancer
Study Progression Recurrence
Bosschieter 2017 [18] 15 of 413 pts experienced DP 3-yr RR 20% for immediate MMC instillation vs 32% for delayed MMC
installation
Ojea 2017 [26] DP rate 9.4% for MMC, 9.9% for BCG 27 mg, and
12.9% for BCG 14.5 mg
RR 38.9% for MMC, 26.8% for BCG 27 mg, and 36% for BCG 13.5 mg
Serretta 2010 [27] 10 pts progressed to muscle-invasive disease (3 in
5 weekly Epi instillations arm vs 7 in extended Epi
schedule arm)
3-yr RFR 54.4% for 5 weekly Epi instillations vs 62.1% for extended Epi
schedule (p = 0.11)
3-yr RFS 62.7% for 5 weekly Epi instillations vs 69.5% for extended Epi
schedule
Elsawy 2018 [19] DP 1 event in intravesical Epi arm vs 0 events in
TURBT alone arm
Recurrence: 4 events in intravesical Epi arm vs 4 events in TURBT alone arm
Gupta 2020 [22] NR Recurrence: 0/7 for monthly BCG for 12 doses vs 1/7 for BCG per the SWOG
protocol (p = 0.3)
Kelly 2018 [23] DP 3 pts (4.3%) treated with TURBT + MMC (IR) or
BCG (HiR) + celecoxib vs 1 pt (1.7%) treated with
TURBT + MMC (IR) or BCG (HiR) + placebo (p = 0.6).
3-yr RFR 52% for TURBT + MMC (IR) or BCG (HiR) + celecoxib vs 50% for
TURBT + MMC (IR) or BCG (HiR) + placebo (HR 0.90, log-rank p = 0.7).
Naya 2018 [24] DP not noted during this period in any patient 3-yr RFS 63.4% for single immediate THP installation vs 86.1% for additional
THP installations (log-rank test, p < 0.01)
Oddens 2012 [25] NR DFI for 1/3 BCG dose: 106 events/192 pts for 1-yr maintenance vs 97 events/
218 pts for 3-yr maintenance (HR 1.35, 95% CI 1.03–1.79)
DFI for full BCG dose: 72 events/191 pts for 1-yr maintenance vs 81 events/
188 pts for 3-yr maintenance (HR 0.88, 95% CI 0.64–1.21)
Sylvester 2009 [28] 9.2-yr DP 7.1% for Epi vs 4.0% for BCG (HR 0.56, 95%
CI 0.26–1.23; p = 0.14)
DP or DM 13.5% for Epi vs 5.2% for BCG (HR 0.39,
95% CI 0.21–0.73; p = 0.002)
9.2-yr RR 58.8% for epirubicin vs 40.1% for BCG (HR 0.59, 95% CI 0.45–0.76; p
< 0.001)
DM 8.8% for epirubicin arm vs 3.7% for BCG (HR 0.42, 95% CI 0.20–0.90; p =
0.027)
Turkeri 2010 [29] Grade and stage progression: 1.5% for single
instillation vs 4% for double instillation (p = 0.165)
RR 14.7% for single instillation vs 21.3% for double instillation (p = 0.305)
Xu 2015 [20] NR 2-yr RR 26.8% for laser + THP vs 30% for TURBT + THP
Zhang 2015 [21] NR 1-yr RR 54.5% for TURBT + Epi vs 51.2% for LVRBT + Epi (HR 0.935, 95% CI
0.62–1.42; p = 0.752)
3-yr RR 68.2% for TURBT + Epi vs 65.1% for LVRBT + Epi (HR 0.933, 95% CI
0.59–1.47; p = 0.762)
BCG = bacillus Calmette-Guérin; CI = confidence interval; DFI = disease-free interval; DM = distant metastasis; DP = disease progression; Epi = epirubicin; HiR =
high risk; HR = hazard ratio; IR = intermediate risk; LVRBT = laser vaporesection of bladder tumor; MMC = mitomycin C; NR = not reported; THP = pirarubicin;
TURBT = transurethral resection of bladder tumor; pt = patient; RFR = recurrence-free rate; RFS = recurrence-free survival; RR = recurrence rate.
E U R O P E A N U R O L O G Y F O C U S X X X ( 2 0 2 1 ) X X X – X X X6
EUF-1092; No. of Pages 106 instillations of epirubicin: immediate epirubicin after
TURBT + 5 weekly instillations] or [total of 9 installations
with MMC 40 mg: immediate within 24 h after TURBT
instillation + 3 weekly instillations + 5 monthly instilla-
tions]); (2) chemotherapy as a delayed regimen (total of
9 installations with MMC 40 mg: instillation starting 2 wk
after TURBT + 3 weekly instillations + 5 monthly instilla-
tions); (3) chemotherapy as an extended regimen ([total of
16 instillations of epirubicin: immediate epirubicin after
TURBT + 5 weekly instillations + 10 monthly instillations]
OR [MMC 30 mg given once a week for 6 wk followed by
another 6 instillations given once every 2 wk during
12 wk]; (4) immunotherapy at full dose (BCG 27 mg given
once a week for 6 wk followed by another 6 instillations
given once every 2 wk during 12 wk); and (5) immuno-
therapy at a reduced dose (BCG 13.5 mg given once a week
for 6 wk followed by another 6 instillations given once
every 2 wk during 12 wk). The networks of eligible com-
parisons are graphically represented in a network plot of
the association of treatment regimen with 5-yr recurrence
risk in Figure 2. Network plots show interconnections
between different therapy regimens (represented by a
node). Connections between different therapy regimens
are represented by links; numbers indicate the number of
studies.Please cite this article in press as: Laukhtina E, et al. Intravesical Th
Bladder Cancer: A Systematic Review and Network Meta-analysis
10.1016/j.euf.2021.03.016An NMA of the five intravesical therapy regimens listed
above was conducted with regard to the 5-yr recurrence risk
in intermediate-risk NMIBC (Fig. 3). Chemotherapy in the
extended regimen was associated with a lower likelihood of
5-yr recurrence compared to chemotherapy in the standard
regimen (OR 0.51, 95% CI 0.26–1.03). By contrast, a delayederapy in Patients with Intermediate-risk Non–muscle-invasive
 of Disease Recurrence. Eur Urol Focus (2021), https://doi.org/
Fig. 3 – Forest plot showing the association of treatment with the 5-yr
recurrence risk in intermediate-risk non–muscle-invasive bladder
cancer. OR = odds ratio; CI = confidence interval.
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cantly lower likelihood of 5-yr recurrence compared to
standard chemotherapy (OR 0.92, 95% CI 0.58–1.48). Simi-
larly, compared to a standard chemotherapy regimen,
immunotherapy, regardless of whether at a full or reduced
dose, was not associated with a significantly lower likeli-
hood of 5-yr recurrence (OR 0.90, 95% CI 0.39–2.11, and OR
0.93, 95% CI 0.40–2.19, respectively). According to the anal-
ysis of treatment ranking, it is highly likely that chemother-
apy in the extended regimen has the lowest rate of the 5-yr
recurrence (P score 0.9666). The treatment ranking of other
therapies is presented in Supplementary Table 2.
3.4. Discussion
We performed a systematic review of the oncologic out-
comes of intravesical therapy for patients with intermedi-
ate-risk NMIBC. We also performed an NMA to indirectly
compare the association of different intravesical therapy
regimens with the 5-yr recurrence risk. This approach led to
several interesting findings.
First, according to our results, chemotherapy in the
extended regimen (with maintenance) was associated with
the lowest likelihood of 5-yr recurrence for patients with
intermediate-risk NMIBC. Therefore, immediate intravesi-
cal chemotherapy instillation after TURBT and then five or
six weekly instillations followed by prolonged monthly
instillations or instillations given once every 2 wk for a
few months is the regimen that provides the best long-term
oncologic outcomes in terms of recurrence in intermediate-
risk NMIBC. This supports the AUA guidelines recommend-
ing 6 wk of induction intravesical chemotherapy with
maintenance for an unspecified duration in intermediate-
risk NMIBC [30]. At the same time, some of the studies
included reported intravesical chemotherapy with mainte-
nance for up to 12 wk that is not the regimen recommended
by the current guidelines. This therapy might be used
according to historic recommendations before the current
treatment strategies. Nevertheless, our analysis does not
reflect the impact of intravesical therapy on progression
risk, which may also pose a challenge in identifying the
optimal treatment options for intermediate-risk NMIBC.
Second, we found that chemotherapy delayed for 2 wk
after TURBT was not significantly associated with a lower
likelihood of 5-yr recurrence when compared to standard
chemotherapy in intermediate-risk NMIBC. The EAU guide-
lines indicate that repeat chemotherapy instillationsPlease cite this article in press as: Laukhtina E, et al. Intravesical Th
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regardless of a previous single instillation immediately after
TURBT [13]. Sylvester et al [31] reported that a single
instillation of chemotherapy immediately after TURBT com-
pared to TURBT alone reduces the risk of recurrence in
NMIBC, except for patients at high risk of recurrence
because of its lack of efficacy in this subgroup. In their
meta-analysis, Sylvester et al also provide evidence that
the use of postoperative irrigation also reduces recurrences,
which can be explained by a role in preventing implantation
of circulating tumor cells at the site of resection. Unfortu-
nately, data on postoperative irrigation use in the studies
included in our NMA are lacking. Moreover, no study has
reported results for combination therapy, although it was
previously shown that combination therapy might provide
prophylactic advantage in terms of recurrence when com-
pared to BCG therapy alone for patients with intermediate-
and high-risk NMIBC [32].
Interestingly, immunotherapy with BCG, regardless of
the doses used, was not associated with a significantly
lower likelihood of 5-yr recurrence compared to chemo-
therapy for patients with intermediate-risk NMIBC in our
analysis. Hence, it seems that BCG instillations do not
provide long-term benefits over chemotherapy in interme-
diate-risk NMIBC. This is particularly important because of
the current worldwide shortage of BCG [33]. In contrast to
our results, a previous meta-analysis found that 27 mg BCG
was more effective than 13.5 mg BCG in reducing tumor
recurrences (risk ratio 0.66, 95% CI 0.49–0.89; p = 0.006)
[34]. Astram et al included both intermediate- and high-risk
NMIBC without subgroup analysis in their meta-analysis,
while our NMA included only patients with intermediate-
risk NMIBC. However, it should be stressed that the article
included in our NMA did not use the maintenance schedule
of BCG therapy, which was shown to be more effective in
preventing recurrence. For example, Han et al [35] recom-
mended adjuvant intravesical BCG with maintenance ther-
apy for patients with papillary carcinoma. Chemotherapy or
BCG plus chemotherapy was not better than BCG alone in
preventing tumor recurrence [35]. Supporting these results,
another meta-analysis showed that maintenance BCG was
superior to MMC in preventing disease recurrence [36]. The
discrepancy in these results can probably be attributed to
the inclusion of all NMIBC patients regardless of risk group.
Nevertheless, as both the EAU and AUA guidelines recom-
mend 1-yr BCG maintenance in intermediate-risk NMIBC
[13,30], most of the studies included highlight the poor
compliance with NMIBC guidelines worldwide [37].
Another challenge in interpreting the results of the
studies included is the lack of data on some relevant clini-
copathologic features. The studies included did not take into
account adverse pathologic features such as tumor extent
and variant histology, which are associated with worse
oncologic outcomes and suboptimal response to intravesi-
cal therapies [12,38–40]. The introduction of immune
checkpoint inhibition (CPI) and its combinations might
provide a further understanding of the role of intravesical
therapy in intermediate-risk NMIBC. A few ongoing trials
are evaluating the role of intravesical CPI in intermediate-erapy in Patients with Intermediate-risk Non–muscle-invasive
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safety, tolerability, and efficacy of intravesical or intrave-
nous pembrolizumab (NCT03167151). In addition, in the
current era of personalized medicine, molecular biomarkers
are promising tools for predicting patient response to intra-
vesical chemotherapy and immunotherapy [41]. However,
none of the studies included provided data on biomarkers
expression or their predictive role. We believe that tissue-
based and urine-based molecular biomarkers hold promise
for changing the management of intermediate-risk NMIBC.
The main strength of our systematic review and NMA is
that, to the best of our knowledge, it is the first to evaluate
oncologic outcomes of intravesical therapy for patients with
intermediate-risk NMIBC. Nevertheless, there are several
limitations. The main limitation is the significant heteroge-
neity across the studies in terms of different treatment
regimens and definitions of outcomes (endpoints). Hence,
an NMA was feasible only among three studies comparing
different intravesical therapy strategies and only for the 5-
yr recurrence risk. However, the long-term survival differ-
ences may be biased by the treatment received after recur-
rence. Second, the small sample size in most of the studies
included may have limited the power of the studies to
reveal clinically significant findings. Third, the heterogene-
ity in risk stratification definition underlines the necessity
for standardized criteria to facilitate accurate decision-mak-
ing. Fourth, inconsistencies in the intervention regimens
and evaluation of the curative effect in the trials included
might affect the generalizability of our results for patients
with intermediate-risk NMIBC because of different treat-
ment regimens and a heterogeneous case mix. Moreover,
the articles included on celecoxib and comparison of laser
and standard TURBT techniques might provide mixed and
unclear messages to readers. These treatments are not
widely used and current guidelines do not recommend
them. However, patients in these studies underwent intra-
vesical instillation in addition to celecoxib received during
single intravesical MMC instillation following TURBT. Like-
wise, laser therapy was followed by intravesical instillation.
We included these studies in the qualitative evidence syn-
thesis because they matched our inclusion criteria (articles
on patients with intermediate-risk NMIBC treated with
TURBT and/or intravesical therapy). Nevertheless, we did
not include them in the quantitative analysis for the reasons
mentioned above. Although indirect treatment compari-
sons have been used and validated to compare outcomes
from RCTs, this approach falls short of a head-to-head
treatment comparison. Thus, direct and well-designed com-
parative trials are required to validate the findings of our
study.
4. Conclusions
Our analysis indicates that intravesical chemotherapy with
a maintenance regimen confers a superior oncologic benefit
in terms of the 5-yr recurrence risk compared to chemo-
therapy without maintenance for patients with intermedi-
ate-risk NMIBC. Use of a single immediate intravesicalPlease cite this article in press as: Laukhtina E, et al. Intravesical Th
Bladder Cancer: A Systematic Review and Network Meta-analysis
10.1016/j.euf.2021.03.016instillation of chemotherapy did not result in a clear reduc-
tion in the recurrence rate. Regardless of dose regimens,
intravesical BCG immunotherapy does not appear to be
superior to chemotherapy for patients with intermediate-
risk NMIBC. However, owing to the lack of comparative
studies, there is an unmet need for well-designed, large-
scale trials to validate our findings and generate robust
evidence on disease recurrence and progression.
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